WGc-0201 / WestGene Biopharma - LARVOL DELTA

An exploratory study on the mRNA WGc-0201 vaccine against advanced hepatitis B related hepatocellular carcinoma in a prospective open-label and first-in-human clinical trial (ESMO 2025) - P1 | "These favorable outcomes provide a proof-of-concept andsupportfurther exploration of WGc-0201. Legal entity responsible for the study The authors."

Clinical • First-in-human • Metastases • P1 data • Hepatocellular Cancer • Oncology • Solid Tumor • IFNG

WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: West China Hospital

New P1 trial • Hepatocellular Cancer • Oncology • Solid Tumor